EGFR tyrosine kinase inhibitor therapy for lung cancer treatments and their clinical outcomes: A cohort study in Taiwan

Malignant cancer is the top cause of mortality in Taiwan. In particular, the mortality rate of with lung cancer reached 39.2/100,000 in 2017. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are being increasingly used to treat lung cancer.; however, due to small sample sizes...

Descripción completa

Detalles Bibliográficos
Autor principal: Chung, Ching-Hu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6865133/
https://www.ncbi.nlm.nih.gov/pubmed/31788083
http://dx.doi.org/10.3892/ol.2019.10942

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6865133/
https://www.ncbi.nlm.nih.gov/pubmed/31788083
http://dx.doi.org/10.3892/ol.2019.10942

Ejemplares similares